• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Carmell Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    1/24/25 5:00:09 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care
    Get the next $CTCX alert in real time by email
    8-K
    0001842939false0001842939us-gaap:CommonStockMember2025-01-202025-01-2000018429392025-01-202025-01-200001842939us-gaap:WarrantMember2025-01-202025-01-20

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 20, 2025

     

     

    Carmell Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40228

    86-1645738

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2403 Sidney Street, Suite 300

     

    Pittsburgh, Pennsylvania

     

    15203

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 412 894-8248

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CTCX

     

    The Nasdaq Stock Market LLC

    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

     

    CTCXW

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Departure of Kendra Bracken-Ferguson as Chief Executive Officer

    On January 20, 2025, the Company and Kendra Bracken-Ferguson mutually agreed that Ms. Bracken-Ferguson would no longer serve as the Chief Executive Officer of the Company effective as of January 20, 2025.

    In connection with Ms. Bracken-Ferguson’s separation from the Company, she and the Company entered into a separation and release of claims agreement, dated January 24, 2025 (the “Separation Agreement”), pursuant to which Ms. Bracken-Ferguson will receive cash payments in the aggregate amount of $150,000 to be paid in equal installments over six months. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

     

    Appointment of Rajiv Shukla as Chief Executive Officer

     

    Effective as of January 24, 2025, the Company’s Board of Directors appointed Rajiv Shukla, the Company’s current Executive Chairman, as the Chief Executive Officer of the Company. Mr. Shukla will continue to serve in his role as Executive Chairman.

    Rajiv Shukla, age 50, has served as the Company’s Chairman since inception and first served as its Chief Executive Officer until Ms. Bracken-Ferguson’s appointment in July 2024. Additional biographical information regarding Mr. Shukla can be found under “Proposal 1: Election of Directors — Continuing Directors” of the Company’s definitive proxy statement filed with the SEC on June 14, 2024, which is incorporated herein by reference.

    There is no arrangement or understanding between Mr. Shukla and any other person pursuant to which Mr. Shukla was appointed as the Chief Executive Officer. There are no family relationships between Mr. Shukla and any director or executive officer of the Company, and Mr. Shukla is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit

    Description

    10.1

    Separation and Release of Claims Agreement, dated January 24, 2025, by and between Carmell Corporation and Kendra Bracken-Ferguson

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date:

    January 24, 2025

    By:

    /s/ Byran J. Cassaday

     

     

     

    Bryan J. Cassaday
    Chief Financial Officer

     


    Get the next $CTCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CTCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Elevai Skincare Acquisition

    PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. ("Elevai"), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) ("PMGC") and Elevai, its wholly owned subsidiary (the "Acquisition"). At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 mill

    1/16/25 8:00:28 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out

    PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The Private Placement was priced at a slight premium t

    1/3/25 8:00:03 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bracken-Ferguson Kendra

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:13:51 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gregory Kathryn

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Cassaday Bryan J.

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:12 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    SEC Filings

    View All

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:01:17 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:00:09 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/10/25 8:53:40 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Upton Richard A bought $2,336 worth of shares (5,000 units at $0.47), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/16/24 4:30:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Frisch Scott M. bought $515 worth of shares (1,009 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:11 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Gregory Kathryn bought $643 worth of shares (1,260 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:16 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Leadership Updates

    Live Leadership Updates

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

    PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi

    7/29/24 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

    PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co

    3/20/24 4:39:36 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    11/14/24 2:48:40 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Carmell Corporation (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    4/18/24 3:03:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care